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The utilization of trophectoderm biopsy combined with comprehensive chromosome screening (CCS) tests for
embryonic aneuploidy was recently suggested to improve IVF outcome, however, not without criticisms. The
ongoing discussion on the unrestricted clinical adoption of preimplantation genetic screening (PGS) has called for a
proper randomized controlled trial (RCT), aiming to further evaluate the cumulative live birth rates (LBRs) following
a single oocyte retrieval, utilizing all fresh and frozen embryos. Since this study seems not to appear for various
reasons, we present herewith, the hypothetical required RCT based on the hitherto published literature.
After implementing data from the hitherto published literature on blastulation and aneuploidy rates, the rate of
mosaicism and technical errors and implantation rates/LBRs of non-PGS day-3 and blastocyst and PGS blastocyst,
we could clearly demonstrate the superiority of non-PGS embryo (day-3 and blastocyst) transfer over PGS blastocyst
transfer, in terms of cumulative LBR (18.2–50 % vs 7.6–12.6 %, respectively).
We therefore believe that until the proper, non-hypothetical RCT on the efficacy of this procedure will appear, PGS
should be offered only under study conditions, and with appropriate informed consents.
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Introduction
Preimplantation genetic screening (PGS) by blastomere
aspiration of day 3 embryos, followed by ploidy analysis
of these cells using fluorescence in situ hybridization
(FISH), was clearly shown to be ineffective in improving
in vitro fertilization (IVF) pregnancy rates and in reducing
miscarriage rates [1–4]. Recently, the utilization of troph-
ectoderm biopsy (day 5–6 embryos) combined with com-
prehensive chromosome screening (CCS) tests for
embryonic aneuploidy, was suggested to improve IVF out-
come [5], however, not without criticisms [6, 7].
The reintroduction of PGS, utilizing of trophectoderm bi-
opsy combined with CCS tests for embryonic aneuploidy,
was based on apparently improved ability to accurately
diagnose embryonic aneuploidies without compromising its
implantation potential. On the other hand, opponents have
claimed that the reported improved efficacy and outcome
are related to various factors [6, 7], including the favorably
selected patients, whose embryos have reached the blasto-
cyst stage, thus, excluding elderly and those with decrease
ovarian reserve and the definition of pregnancy outcomes
per embryo transfer, rather than by intention to treat.
Moreover, while all studies in favor of PGS have
reported on LBR following the first embryo transfer after
a fresh IVF cycle, a clinically more relevant is the cumu-
lative LBR following a single ovarian stimulation and
utilization of all fresh and frozen-thawed embryos after
one oocyte retrieval. We therefore believe, that the on-
going discussion on the unrestricted clinical adoption of
PGS should call for a proper randomized controlled trial
(RCT), aiming to further evaluate the cumulative live
birth rates (LBRs) following a single oocyte retrieval,
utilizing all fresh and frozen embryos. Prompted by the
aforementioned arguments, we will present the required
hypothetical RCT based on the hitherto published
literature.Correspondence: raoul.orvieto@sheba.health.gov.il
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Current PGS clinical data
Several retrospective and prospective trials have reported
improved clinical outcomes following PGS, utilizing of
trophectoderm biopsy combined with CCS tests for em-
bryonic aneuploidy. These RCTs and observational stud-
ies have been recently evaluated by Dahdouh et al. [8] in
their meta-analysis, aiming to study whether PGS-CCS
improves clinical implantation rates (IR) and sustained
IR (beyond 20 weeks) compared with routine care for
embryo selection in IVF cycles. Of the 29 eligible arti-
cles, only three RCTs and eight observational studies
met full inclusion criteria, revealing significantly higher
clinical and sustained IRs with the use of PGS-CCS in
patients with normal ovarian reserve.
On the contrary, a recent analysis of national U.S. PGS
data for 2011–2012 have yielded different results [9].
While more PGS than non-PGS cycles reached ET
(64.2 % vs. 62.3 %), suggesting favorable patient selection
bias for patients using PGS, LBRs per cycle start (25.2 %
vs. 28.8 %) and per ET (39.3 % vs. 46.2 %) were signifi-
cantly better in non-PGS cycles, whereas miscarriage
rates were similar (13.7 % vs. 13.9 %).
The hypothetical RCT (Fig. 1)
The required hypothetical RCT should include 3 groups
of patients with comparable clinical characteristics: those
undergoing unscreened (non-PGS) day-3 transfer; those
undergoing non-PGS blastocyst transfer; and those under-
going screened (PGS) blastocyst transfer.
For the propose of the analysis, we will assume that
each group yielded 100 day-3 embryos and that all
embryos underwent vitrification with optimal results
(100 % survival post thawing).
Moreover, in order to procceed with the analysis, we need
precise estimation of the following data from the hitherto
published literature: blastulation rate, aneuploidy rate, the
rate of mosaicism and technical errors and IRs/LBRs of
non PGS day-3 and blastocyst and PGS blastocyst.
Blastulation rate
According to a comprehensive cochrane review that
analyzed cleavage stage versus blastocyst stage embryo
transfer in assisted reproductive technology [10], the range
of blastocyst formation rates across studies varied between
28 and 97 %. With a mean blastulation rate of 47 %.
Aneuploidy rate
Franasiak et al. [11] have presented their clinical experi-
ence while reviewing 15,169 consecutive trophectoderm
biopsies evaluated with CCS. As expected, the preva-
lence of aneuploidy rose steadily with age. The preva-
lence of aneuploidy was 20 to 27 % in women 26 to
30 years of age, rose steadily from age 31 through age
43, and then plateaued at approximately 85 %. Among
the biopsies with aneuploidy, 64 % involved a single
chromosome, 20 % two chromosomes, and 16 % three
chromosomes, with the proportion of more complex an-
euploidy increasing with age. The calculated overall an-
euploidy risk across all screened blastocysts was 59 %.
Mosaicism and technical errors
In a recent study [12] evaluating the accuracy of troph-
ectoderm multiple biopsies using next-generation
Fig. 1 The required hypothetical RCT
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sequencing (NGS), 5 of the 24 (20.8 %) trophectoderm
biopsies revealed inconclusive results, while 4 (16.6 %)
demonstrated embryonic mosaicism. When considering
only NGS results without a background noise, discord-
ant results (mosaicism) were observed in 3 out of the 8
embryos. Moreover, 3 of the 18 (16.6 %) trophectoderm
biopsies were inconclusive. Overall, 8 (36.3 %) of the 22
biopsies without a background noise revealed mosaicism
or inconclusive results.
In agreement with the aforementioned observation,
Greco et al. [13] have recently showed that mosaic em-
bryos can develop into healthy euploid newborns. Of 18
patients undergoing a transfer of a mosaic embryo, 6
conceived and delivered a normal euploid infant at term.
We therefore should not ignore the possibility of misdiag-
nosis, which may lead to false positive and false negative re-
sults. While a false positive result, such as those describe by
Greco et al. [13], may reduce IVF outcome because a
healthy embryo is not transferred, a false negative result,
where an abnormal embryo is transferred, will lead to the
delivery of an “abnormal/aneuploid” child. As a conse-
quence of these observations, whatever the outcome
following PGS blastocyst transfer would be, the LBR would
be even lower due to the mosaicism and technical errors.
Implantation and live birth rates
A recently published CDC report [14] has presented the
data regarding the percentages of day 3 and day 5 em-
bryo transfers resulting in live births, by age group. Live
birth rates following day 3 embryo transfer ranges be-
tween 23.1 and 38.5 % (crude mean 31.2 %) in patients
age 38–40 vs <35 years, respectively. The corresponding
figures following non-PGS blastocyst transfer were 35.5
and 52.5 % (crude mean 38.8 %) respectively.
While reviewing the effect of elective single embryo
transfer compared with double embryo transfer follow-
ing IVF, Min et al. revealed ongoing pregnancy/Live
birth rates per cleaved embryo transfer, ranging between
21.4 and 38.5 % [15].
Moreover, the sustained implantation rate of day-3
embryo reached 50 % in Scott et al. report, while evalu-
ating the effect of embryo biopsy on reproductive
competence [16].
A close look at Dahdouh et al. [8] meta-analysis
revealed a sustained IR (beyond 20 weeks) of 65.5 % for
PGS-blastocyst, as compared to 47.2 % for non-PGS
blastocyst, figures that are in accordance with Scott et al.
[17]. The corresponding figures, as reported by the ana-
lysis of national U.S. PGS data for 2011–2012, are
39.3 % vs. 46.2 %, respectively [9].
To summarize, the reported/expected sustained IRs
per day-3 non-PGS embryos, PGS and non-PGS blas-
tocysts range between 21.4 and 50 %, 44 and 47.2 %
and 39.3 and 65.5%, respectively.
Data analysis (Fig. 1)
Implementation of the aforementioned figures to the hypo-
thetical RCT analysis reveals the highest LBR in patients
undergoing non-PGS day 3 embryo transfer (21.4–50 %),
followed by Non-PGS blastocyst (18.2–22.2 %). Patients
undergoing PGS blastocysts transfer achieved the lowest
LBR (7.6–12.6 %).
Conclusions
In the present hypothetical RCT, we clearly demon-
strated the superiority of non-PGS embryo transfer over
PGS blastocyst transfer, in terms of cumulative LBR
(18.2–50 % vs 7.6–12.6 %, respectively). These figures
are in accordance with the recently raised debate [17]
regarding the risks and benefits of extended embryo cul-
ture. Maheshwari et al. [18] have demonstrated that
although blastocyst transfer results in higher LBRs per
embryo transfer episode, it ultimately results in lower
cumulative live birth rates per couple, higher risk of pre-
term birth, large for gestational age, monozygotic twins
and congenital anomalies compared with embryo transfer
at cleavage stage.
The present analysis adds further information to the
hitherto published data and may contribute to the on-
going discussion on the unrestricted clinical adoption of
PGS, that we believe that until the proper, real, non-
hypothetical RCT on the efficacy of this procedure will
appear, PGS should be offered only under study condi-
tions, and with appropriate informed consents.
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